Rate of serious adverse events · non‐pregnant women with vulvovaginal candidiasis
Probiotics used as adjuvants to conventional antifungal drugs showed no clear difference in rate of serious adverse events compared with conventional antifungal drugs (low certainty).
1 finding from 1 review
Intervention not reported
Maternal serious adverse events · pregnant women
The intervention showed no clear difference in maternal serious adverse events (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Intervention not reported
Serious adverse events for neonate/infant · pregnant women and their babies
The intervention may leads to lower serious adverse events for neonate/infant (low certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with prednisolone (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Intravenous immunoglobulin showed no clear difference in serious adverse events compared with intravenous methylprednisolone (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater
It is very uncertain whether evening changes serious adverse events compared with morning dosing regimen (very low certainty).
1 finding from 1 review
Serious adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Orlistat probably leads to higher serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · hormone‐sensitive prostate cancer
Degarelix showed no clear difference in serious adverse events compared with standard androgen suppression therapy (low certainty).
1 finding from 1 review
Serious adverse events · healthy individuals and those with a pre‐existing health condition
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Preschool children (<6 years)
Intermittent ICS showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with probiotic (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Intervention not reported
Total serious adverse events Systolic targets · Diabetes Mellitus with elevated blood pressure
The intervention showed no clear difference in total serious adverse events Systolic targets (low certainty).
1 finding from 1 review
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review